Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital.

Pritmohinder S Gill1,2, Feliciano B Yu3, Patricia A Porter-Gill2

  • 1Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA.

Journal of Personalized Medicine
|June 2, 2021
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.

Cardiology and therapy·2026
Same author

Photo Quiz: Persistent eyelash debris in a 10-year-old female.

Journal of clinical microbiology·2026
Same author

Photo Quiz: An infant with cough and lymphocytosis.

Journal of clinical microbiology·2026
Same author

Photo Quiz: An infant with altered mental status.

Journal of clinical microbiology·2026
Same author

Photo Quiz: Persistent papules in an immunocompromised child.

Journal of clinical microbiology·2026
Same author

Health Care Providers' Practices and Perspectives on Discussing Life Expectancy With Patients With Duchenne Muscular Dystrophy and Their Caregivers.

Pediatric neurology·2026
Summary

Pharmacogenomics testing guides pediatric medication dosing, reducing risks of adverse events and ineffective treatments. Arkansas Children's Hospital implemented a clinical test for 66 pediatric drugs, enhancing patient care through precision medicine.

Area of Science:

  • Pharmacogenomics
  • Precision Medicine
  • Clinical Laboratory Science

Background:

  • Pharmacogenomics (PGx) is integral to precision medicine, predicting medication response and adverse events.
  • The US FDA recognizes over 280 drugs with biomarker-based dosing guidance.
  • Adverse drug events and sub-therapeutic responses pose significant risks in pediatric populations.

Purpose of the Study:

  • To describe the development and implementation of a clinical pharmacogenomics test at Arkansas Children's Hospital (ACH).
  • To provide genotype-guided dosing recommendations for 66 pediatric medications.
  • To integrate PGx results into the electronic health record for clinical decision support.

Main Methods:

  • Development of a laboratory-based PGx test analyzing 174 single nucleotide polymorphisms (SNPs) across 23 clinically actionable PGx genes.
Keywords:
best practice alerts (BPAs)clinical decision support (CDS)electronic health records (EHR)genomic indicatorsgenotypepediatricspharmacogenomics (PGx)phenotype

Related Experiment Videos

  • Processing of individual genotypes into star-allele and phenotype formats for discrete per-gene results.
  • Integration of PGx data into the EPIC Electronic Health Record (EHR) to create genomic indicators for clinical decision support (CDS).

    • Main Results:

    • Successful implementation of a clinical PGx test at ACH tailored for pediatric use.
    • The test provides genotype-guided dosing for 66 pediatric medications.
    • Genomic indicators within EPIC-EHR facilitate clinician access to PGx-based dosing guidance.

    Conclusions:

    • The ACH clinical PGx test offers a valuable tool for optimizing pediatric medication therapy.
    • Integration into the EHR enhances the utility of PGx testing for clinical decision-making.
    • This initiative advances the application of pharmacogenomics in pediatric precision medicine.